Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Autor:	Brunner AM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Blonquist TM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., DeAngelo DJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., McMasters M; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Fell G; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Hermance NM; Department of Biology, Worcester Polytechnic Institute, Worcester, MA, USA., Winer ES; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lindsley RC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Hobbs GS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Amrein PC; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Hock HR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Steensma DP; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Garcia JS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Luskin MR; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Stone RM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ballen KK; Division of Hematology-Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA., Rosenblatt J; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Avigan D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Nahas MR; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Mendez LM; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., McAfee SL; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Moran JA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Bergeron M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Foster J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Bertoli C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Manning AL; Department of Biology, Worcester Polytechnic Institute, Worcester, MA, USA., McGregor KL; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Fishman KM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Kuo FC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Baltay MT; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Macrae M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Burke M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Behnan T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Wey MC; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Som TT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Ramos AY; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Rae J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Lombardi Story J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Nelson N; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Logan E; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Connolly C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Neuberg DS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Chen YB; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Graubert TA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Fathi AT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: afathi@partners.org.
Jazyk:	angličtina
Zdroj:	The Lancet. Haematology [Lancet Haematol] 2020 Feb; Vol. 7 (2), pp. e122-e133. Date of Electronic Publication: 2019 Dec 11.
DOI:	10.1016/S2352-3026(19)30203-0
Abstrakt:	Background: Increased aurora A kinase (AAK) expression occurs in acute myeloid leukaemia; AAK inhibition is a promising therapeutic target in this disease. We therefore aimed to assess the activity of alisertib combined with 7 + 3 induction chemotherapy in previously untreated patients with high-risk acute myeloid leukaemia. Methods: We did a single-arm, phase 2 trial of patients recruited from the Dana-Farber/Harvard Cancer Center in the USA. Eligible patients had previously untreated acute myeloid leukaemia, an Eastern Cooperative Oncology Group performance status of 0-2, and were at high risk of disease as defined by the presence of an adverse-risk karyotype, the presence of secondary acute myeloid leukaemia arising from previous myelodysplastic syndrome or myeloproliferative neoplasm, the presence of therapy-related acute myeloid leukaemia, or being 65 years or older. Enrolled patients received 7 + 3 induction chemotherapy of continuous infusion of cytarabine (100 mg/m 2 per day on days 1-7) and intravenous bolus of idarubicin (12 mg/m 2 per day on days 1-3). Oral alisertib (30 mg) was given twice per day on days 8-15. Patients could receive up to four consolidation cycles with cytarabine and alisertib, and alisertib maintenance for 12 months. The primary endpoint was a composite including the proportion of patients achieving complete remission and those with a complete remission with incomplete neutrophil or platelet count recovery. Analyses were per-protocol. This study is registered with Clinicaltrials.gov, number NCT02560025, and has completed enrolment. Findings: Between Dec 31, 2015, and Aug 1, 2017, we enrolled a total of 39 eligible patients. 19 (49%) of 39 patients had secondary acute myeloid leukaemia and three (8%) had therapy-related acute myeloid leukaemia. At mid-induction, 33 (85%) of 39 patients showed marrow aplasia, six (15%) received re-induction. The median follow-up was 13·7 months (IQR 12·7-14·4). Composite remission was 64% (two-stage 95% CI 48-79), with 20 (51%) of 39 patients achieving complete remission and five (13%) achieving complete remission with incomplete neutrophil or platelet count recovery. The most common grade 3 or 4 adverse events included febrile neutropenia (16 [41%] of 39), neutropenia (12 [31%]), thrombocytopenia (13 [33%]), anaemia (11 [28%]), anorexia (nine [23%]), and oral mucositis (four [10%]). No treatment-related deaths were observed. Interpretation: These results suggest that alisertib combined with induction chemotherapy is active and safe in previously untreated patients with high-risk acute myeloid leukaemia. This study met criteria to move forward to a future randomised trial. Funding: Millennium Pharmaceuticals. (Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu